Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
The product is approved as bioequivalent to Xigduo XR for the indications outlined in the reference drug’s labelling
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
The initiative is aimed at strengthening the district-level screening and chronic disease management infrastructure
Subscribe To Our Newsletter & Stay Updated
